Fresenius Medical Care

Fresenius Kidney Care’s new dialysis nurse residency program for graduate nurses, called the “first of its kind in dialysis” in a company press release, has supported more than 175 recent graduates.

Fresenius Medical North America reports growth in the number of patients on home hemodialysis who utilize the company’s connected health platform, with adoption increasing more than 44% in the past year, according to a press release.

Fresenius Medical Care AG has invested an additional $25 million in clinical-stage biotechnology platform company Humacyte Inc., following an initial investment of $150 million made in 2018.

Texas legislators passed a bill with bipartisan support that mandates end-stage renal disease facilities develop contingency plans in the event that emergencies like natural disasters cause power outages that disrupt delivery of care.

Fresenius Medical Care North America has promoted Joe Turk, previously the head of Home and Critical Care Therapies, to president of the company’s Renal Therapies Group.

Fresenius Medical Care North America has initiated use of a cloud-based connected health platform to better manage patients on peritoneal dialysis, according to a press release.

InterWell Health closed a Series B, $46 million round of equity funding, partnering with more than 1,000 nephrologist investors and 55 nephrology practices across 31 states, according to a company press release.

Building on a previous partnership, Fresenius Medical Care North America will provide home dialysis technology to DaVita patients, according to a press release.

Dialysis providers from across the United States were happy to hear last month that the Biden administration approved federal distribution of the COVID-19 vaccine to dialysis clinics so they can begin vaccinating patients and staff.

The CDC has authorized Fresenius Medical Care North America and DaVita Inc. to serve as distributors of the COVID-19 vaccine to dialysis clinics across the United States, officials reported last week.